LOPROX Drug Patent Profile

When do Loprox patents expire, and when can generic versions of Loprox launch?

Loprox is a drug marketed by Medimetriks Pharms and Bausch and is included in three NDAs.

The generic ingredient in LOPROX is ciclopirox. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ciclopirox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Loprox

A generic version of LOPROX was approved as ciclopirox by FOUGERA PHARMS on August 6^th, 2004.

Summary for LOPROX

US Patents:	0
Applicants:	2
NDAs:	3

US Patents and Regulatory Information for LOPROX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Medimetriks Pharms	LOPROX	ciclopirox	CREAM;TOPICAL	018748-001	Dec 30, 1982	AB	RX	Yes	Yes
Bausch	LOPROX	ciclopirox	SHAMPOO;TOPICAL	021159-001	Feb 28, 2003		DISCN	Yes	No
Medimetriks Pharms	LOPROX	ciclopirox	SUSPENSION;TOPICAL	019824-001	Dec 30, 1988	AB	RX	Yes	Yes

International Patents for LOPROX

See the table below for patents covering LOPROX around the world.

Country	Patent Number	Title	Estimated Expiration
Malaysia	125674	USE OF 1-HYDROXY-2-PYRIDONES FOR THE TREATMENT OF SEBORRHEIC DERMATITIS
Malaysia	7300458	1-HYDROXY-2-PYRIDONES AND PROCESS FOR THEIR MANUFACTURE
South Korea	20000048613
Sweden	348729
Finland	50334

LOPROX Market Analysis and Financial Projection

Last updated: February 3, 2026

What is LOPROX and its role in the pharmaceutical market?

LOPROX is a topical antifungal medication primarily containing ciclopirox, used to treat dermatophyte and yeast infections such as tinea pedis, tinea corporis, tinea cruris, and candidiasis. It is marketed under various brand names, with LOPROX being a common formulation. The drug is widely available in over-the-counter (OTC) and prescription formats across numerous markets, including the United States, Europe, and Asia.

What are the market fundamentals for LOPROX?

Market Size and Revenue

The global topical antifungal market was valued at approximately USD 2.8 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2030, driven by rising incidences of fungal infections and increasing awareness about skincare.

LOPROX constitutes an estimated 2% to 3% of this market, equating to USD 56-84 million in 2022 revenues. The drug’s market share is affected by availability of generics, OTC sales, and regional variations.

Key Markets and Sales Distribution

Region	Market Size (USD billion)	LOPROX Market Share	Estimated Revenue (USD million)
U.S.	1.2	3%	36
Europe	0.8	2.5%	20
Asia-Pacific	0.5	2%	10
Rest of World	0.3	2%	7

This distribution results from regional market dynamics, regulatory environments, and consumer preferences.

What are the drivers influencing LOPROX’s investment scenario?

Patent and Regulatory Status

LOPROX, particularly ciclopirox in topical formulations, faces patent expirations in several key markets. In the U.S., the original patent expired around 2019-2020; subsequent formulations and formulations with delivery improvements may still be under patent protection or regulatory exclusivity.

Regulatory approval for OTC status in major markets enhances sales volume but reduces pricing power. In the European Union, ciclopirox is marketed under multiple approvals, with some formulations authorized as over-the-counter drugs, influencing broader adoption.

Competitive Landscape

The market includes a significant number of generics, reducing overall prices and margins. Key competitors include:

• Terbinafine (Lamisil)
• Butenafine (Mentax)
• Clotrimazole (Lotrimin)

LOPROX’s differentiation lies in the broad spectrum of activity and established safety profile, but price competition limits premium positioning.

R&D and Pipeline Potential

There is limited pipeline development for ciclopirox due to patent expirations and market maturity. However, research into extended-release formulations, combination therapies, or new delivery systems could influence future growth.

Pricing and Reimbursement

Pricing varies significantly, with OTC formulations priced at USD 10–20 per tube, whereas prescription versions might be higher in cost but covered by insurance or reimbursement programs. Market penetration depends largely on regional insurance policies and cost-effectiveness evaluations.

What are the investment considerations?

Risks

• Patent cliffs and generic competition threaten profit margins.
• Regulatory restrictions or reclassification limits sales volume.
• Market saturation in developed regions constrains growth.

Opportunities

• Expansion in emerging markets with rising dermatological conditions.
• Development of new formulations or combination therapies.
• Strategic licensing or partnerships with local pharma firms.

Financial Outlook

Limited growth potential is forecasted in mature markets; however, volume-driven expansion in emerging economies could sustain moderate revenue streams. Cost pressures from generic competition and price sensitivity restrict profit margins.

What are the strategic recommendations?

• Focus on emerging markets where dermatological disease prevalence is increasing.
• Invest in formulation innovations to extend product lifecycle.
• Consider licensing deals for pipeline expansion or new indications.

Key Takeaways

• LOPROX is a mature antifungal agent with stable, but limited, market share in a highly competitive environment.
• Patent expiration and generic competition have reduced margins.
• Growth opportunities exist primarily in emerging markets and through formulation innovations.
• The overall market growth for topical antifungals is positive but constrained by price competition and market saturation.
• Strategic partnerships and innovation are vital to maintaining relevance and profitability.

FAQs

1. How does patent expiry affect LOPROX’s market value?
Patent expiry opens the market to generics, increasing competition and reducing prices, which diminishes revenue and profit margins.

2. What are the main competitors to LOPROX?
Lamisil (terbinafine), Mentax (butenafine), and clotrimazole are primary competitors, often offering lower-cost alternatives.

3. Is there room for growth in the LOPROX market?
Growth prospects are limited in developed markets but may occur in emerging markets with rising dermatological needs.

4. How does OTC availability influence sales?
OTC status broadens access, increasing sales volume; however, it also reduces pricing power.

5. What future developments could impact LOPROX's market?
Innovations in formulations, new therapeutic indications, and strategic licensing could positively impact its market position.

---

References

[1] MarketWatch, "Global Topical Antifungal Market Size & Trends," 2022.
[2] IQVIA, Data on antifungal drug sales, 2022.
[3] U.S. Patent and Trademark Office, Patent expiration timelines for ciclopirox, 2020.